This first-in-human study of SP16, a novel, synthetic LRP1 agonist, demonstrated that a single subcutaneous injection of SP16 up to 0.200 mg/kg (max dose of 12 mg) was well-tolerated and lacked any biochemical effects on coagulation, platelet function and …

Serpin Peptide 16: 一种LRP1激动剂药物，由Serpin Pharma, LLC (Serpin Pharma, LLC)公司最早进行研发，目前全球最高研发状态为临床2期，作用机制: LRP1激动剂 (LDL receptor related protein 1 agonists)，治疗领域: 呼吸系统疾病,其他疾病,免疫系统疾病,感染,神经系统疾病,遗传病与畸形,消化系统疾病,内分泌与代谢疾病,血液及淋巴系统疾病,皮肤和肌肉骨骼疾病,泌尿生殖系统疾病，在研适应症: 急性肺损伤,带状疱疹,嗜酸粒细胞性食管炎，在研机构: Serpin Pharma, LLC。

2023年2月15日 · Here, we tested the therapeutic efficacy of a Low-Density Lipoprotein Receptor-Related Protein 1 (LRP-1) agonistic small peptide drug (SP16) in attenuating HIV replication and the secretion of inflammatory molecules in brain reservoirs.

By selectively isolating a key portion of a natural SERPIN protein, our targeted therapeutic, known as SP16, restores balance to harmful inflammatory environments, creating an entirely new class of therapeutics for unmet medical needs. SP16 uses a selective and precise mechanism to restore inflammatory equilibrium, with no known adverse effects.

2024年7月8日 · SERPIN-Derived Small Peptide (SP16) as a Potential Therapeutic Agent against HIV-Induced Inflammatory Molecules & Viral Replication in Cells of the CNS

SP16 is an innovative peptide derived from the carboxyl-terminus of α1-Antitrypsin (AAT), corresponding to residues 364–380, and contains recognition sequences for the low-density lipoprotein receptor-related protein-1 (LRP1). LRP1 is an endocytic and cell-signaling receptor that regulates inflammation.

SERPIN peptide 16 (SP16) is a synthetic, selective LRP1 agonist. We herein present the results of a study with a single subcutaneous administration of SP16 in 10 patients with STEMI, to appraise its safety and tolerability and explore the effects on the acute inflammatory response, infarct size, and cardiac function.

Unlike existing treatments, which suppress the immune response, SP16 enhances the body’s innate mechanism for resolving inflammation. Our therapeutic restores immune balance by targeting a receptor that plays a key role in mitigating inflammation. This platform technology has the potential to treat a wide range of inflammatory diseases.

Small peptide 16 (SP16) is a short linear synthetic molecule developed by Serpin Pharma for treating autoimmune and inflammatory diseases [25, 29, 31]. SP16 contains the 5-amino acids sequence derived from the endogenous serine protease inhibitor, α-1-antitrypsin (A1AT), responsible for binding to LRP-1 [25].

2022年11月1日 · SERPIN peptide 16 (SP16) is a synthetic, selective LRP1 agonist. We herein present the results of a study with a single subcutaneous administration of SP16 in 10 patients with STEMI, to appraise its safety and tolerability and explore the effects on the acute inflammatory response, infarct size, and cardiac function.